SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Global Breast Cancer Market Forecasts and Opportunities, 2018 Featuring Astrazeneca, Eli Lilly and Co, F. Hoffmann-La Roche, Novartis AG & Sanofi-Aventis

[July 07, 2014]

Research and Markets: Global Breast Cancer Market Forecasts and Opportunities, 2018 Featuring Astrazeneca, Eli Lilly and Co, F. Hoffmann-La Roche, Novartis AG & Sanofi-Aventis

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/nz9l9w/global_breast) has announced the addition of the "Global Breast Cancer Market 2014-2018" report to their offering.

The Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.

According to the report, one of the major drivers is the increase in death rate because of breast cancer. The incidence and prevalence rate of breast cancer is growing continuously, mainly because of the adoption of sedentary forms of life and increased urbanization accompanied by increased life expectancy. In 2012, the breast cancer mortality rate globally was 12.9 percent. In 2014, there were 40,000 breast cancer deaths in females and 430 breast cancer deaths in males in the US. Thus, an increased death rate because of breast cancer might lead to more people opting for breast cancer treatment.

This report covers the present scenarioand the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:


  • HER2-negative breast cancer
  • HER2-positive breast cancer
  • Hormone receptor positive breast cancer
  • Hormone receptor negative breast cancer
  • Advanced breast cancer
  • Early breast cancer
  • Operable node positive breast cancer
  • Metastatic breast cancer
  • Triple Negative Breast Cancer

Further, the report states that poor diagnosis and screening of breast cancer during the initial stages pose a challenge to the market. Thus, late-stage breast cancer diagnosis is one of the factors that limits the effectiveness of a treatment, despite its availability.

Key Vendors

  • Astrazeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi-Aventis

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Introduction
  6. Market Landscape
  7. Treatment Regimen for Breast Cancer
  8. Market Segmentation by Type of Therapy
  9. Market Segmentation by Molecule Type
  10. Global Monoclonal Antibodies Market in Breast Cancer
  11. Clinical Pipeline Portfolio
  12. Geographical Segmentation
  13. Buying Criteria
  14. Market Growth Drivers
  15. Drivers and their Impact
  16. Market Challenges
  17. Impact of Drivers and Challenges
  18. Market Trends
  19. Trends and their Impact
  20. Vendor Landscape
  21. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/nz9l9w/global_breast


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.